Table 2

Patient and disease characteristics

VariableNo. (%) of patients
No. of patients 1007 
Patient age, y, range (median) 1-75 (45) 
Sex (male/female) 588 (58)/419 (42) 
De novo MDS 771 (77) 
Secondary MDS 236 (23) 
    Antecedent disorders* 228 (23) 
    Prior therapy 374 (37) 
FAB/WHO classification  
    RA 377 (37.4) 
    RCMD 82 (8.1) 
    MDS-U 25 (2.5) 
    RARS 15 (1.5) 
    RAEB§ 304 (30.2) 
        RAEB-1 46 (4.5) 
        RAEB-2 42 (4.2) 
    RAEB-T 91 (9.1) 
    tAML 113 (11.2) 
Cytogenetics  
    IPSS  
        Good 434 (43.1) 
        Intermediate 182 (18.1) 
        Poor 304 (30.2) 
    5-group  
        Very good 13 (1.3) 
            MK+/MK−/unknown 0/13/0 
        Good 440 (43.7) 
            MK+/MK−/unknown 0/440/0 
        Intermediate 175 (17.4) 
            MK+/MK−/unknown 7/167/1 
        Poor 148 (14.7) 
            MK+/MK−/unknown 60/88/0 
        Very poor 97 (9.6) 
            MK+/MK−/unknown 89/8/0 
        Data incomplete 134 (13.3) 
VariableNo. (%) of patients
No. of patients 1007 
Patient age, y, range (median) 1-75 (45) 
Sex (male/female) 588 (58)/419 (42) 
De novo MDS 771 (77) 
Secondary MDS 236 (23) 
    Antecedent disorders* 228 (23) 
    Prior therapy 374 (37) 
FAB/WHO classification  
    RA 377 (37.4) 
    RCMD 82 (8.1) 
    MDS-U 25 (2.5) 
    RARS 15 (1.5) 
    RAEB§ 304 (30.2) 
        RAEB-1 46 (4.5) 
        RAEB-2 42 (4.2) 
    RAEB-T 91 (9.1) 
    tAML 113 (11.2) 
Cytogenetics  
    IPSS  
        Good 434 (43.1) 
        Intermediate 182 (18.1) 
        Poor 304 (30.2) 
    5-group  
        Very good 13 (1.3) 
            MK+/MK−/unknown 0/13/0 
        Good 440 (43.7) 
            MK+/MK−/unknown 0/440/0 
        Intermediate 175 (17.4) 
            MK+/MK−/unknown 7/167/1 
        Poor 148 (14.7) 
            MK+/MK−/unknown 60/88/0 
        Very poor 97 (9.6) 
            MK+/MK−/unknown 89/8/0 
        Data incomplete 134 (13.3) 

MDS-U indicates myelodysplastic syndrome, unclassified.

*

Among these, 54 had aplastic anemia and 8 had Fanconi anemia or other constitutional marrow failure states; 20 had Crohn disease, juvenile rheumatoid arthritis, or other autoimmune disorders; 9 had myeloproliferative neoplasms that evolved to MDS, 56 had Hodgkin or non-Hodgkin lymphoma, and 5 had multiple myeloma. Seventeen had previously been treated for other lymphoid or myeloid leukemias and 57 for solid tumors; 4 had received solid organ transplants, 2 had been accidentally exposed to radiation, and in 4 patients the etiology could not be ascertained.

Unknown in 34.

WHO categories defined only in more recent patients; RA includes patients with RCMD transplanted in earlier years.

§

In 139 patients with RAEB (categorized by FAB), a breakdown into RAEB-1 and RAEB-2 was not possible.

Close Modal

or Create an Account

Close Modal
Close Modal